Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884692 | 0.88 | ABL1 (1.00) | ABL1 | |
| SCHEMBL21884698 | 0.87 | ABL1 (0.81) | ABL1 | |
| SCHEMBL21885524 | 0.86 | ABL1 (1.00) | ABL1 | |
| SCHEMBL21884313 | 0.86 | ABL1 (1.00) | ABL1 | |
| SCHEMBL22871714 | 0.86 | ABL1 (0.61) | ABL1 | |
| SCHEMBL21884304 | 0.86 | ABL1 (1.00) | ABL1 | |
| SCHEMBL21884199 | 0.85 | ABL1 (1.00) | ABL1 | |
| SCHEMBL21884228 | 0.85 | ABL1 (1.00) | ABL1 | |
| SCHEMBL21884214 | 0.84 | ABL1 (1.00) | ABL1 | |
| SCHEMBL21820599 | 0.83 | ABL1 (0.81) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454524-B2 | (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias | TERNS PHARMACEUTICALS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250276961-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250243184-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. | 2025-07-31 | — | — | US | disclosed |
| CN-115448908-B | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-115215838-B | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-12240835-B2 | Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity | TERNS PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240101536-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | TERNS PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-115448908-A | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115215838-A | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-112770745-B | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112770745-A | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | Terns, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | Terns, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240835-B2 | Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity | ABL1, BCR, ABL2 | ABL1 1/4885 |
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | ABL1 1/4885 |
| US-20250276961-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | ABL1 1/4885 |
| US-20250243184-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | ABL1 1/4885 |
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | ABL1, ABL2, BCR | ABL1 1/4885 |
| US-12454524-B2 | (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias | ABL1, ABL2, BCR | ABL1 1/4885 |
| US-20240101536-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.